Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    Hormones & Endocrine (Non-GH)Preclinical

    Gonadorelin Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Gonadorelin dosing — protocols, safety, and where to buy.

    Dosage Calculator

    Calculate exact dosing for Gonadorelin.

    Dosing Protocols

    Beginner

    Context: This section focuses on men's off-label TRT-adjunct use. Women's fertility applications (pump-based ovulation induction, puberty induction) require reproductive endocrinology supervision and are not addressed in DIY protocols.

    Preparation Phase (Weeks -2 to 0):

    • Confirm TRT plan with physician
    • Baseline labs: total testosterone, free testosterone, LH, FSH, estradiol (sensitive assay), SHBG, CBC, CMP, PSA (men 40+), semen analysis if fertility is a goal
    • Testicular volume assessment (orchidometer or ultrasound baseline)
    • Obtain gonadorelin from reputable compounding pharmacy with USP-grade peptide verification
    • Purchase supplies: 29-31G insulin syringes (5/16" or 1/2"), bacteriostatic water, alcohol wipes, sharps container

    Beginner Protocol (Weeks 1-12):

    Dosing Regimen:

    • Gonadorelin 100 mcg subcutaneously, 2x per week
    • Suggested schedule: Monday and Thursday evenings (allows for weekly LH pulse patterns)
    • Timing: evening injection may align with natural nocturnal GnRH pulse patterns in men
    • Duration: 12 weeks initial evaluation

    Reconstitution:

    • 2 mg vial (standard size): reconstitute with 2 mL bacteriostatic water → 1 mg/mL concentration
    • 100 mcg dose = 0.1 mL (10 units on insulin syringe)
    • Alternative: 5 mL BAC water → 0.4 mg/mL → 0.25 mL (25 units) per dose

    Administration:

    • Rotate injection sites: abdomen (2+ inches from navel), lateral thigh, upper arm
    • Clean site with alcohol wipe, let dry fully
    • Pinch skin, insert needle at 45-90° angle (SC), inject slowly
    • Withdraw, apply brief pressure
    • Dispose of needle in sharps container

    Month 1 Evaluation:

    • Symptoms: testicular size/comfort, libido, erectile function, energy, mood
    • No labs needed this early — peptide effects take time
    • Note any injection site reactions

    Month 3 Evaluation (End of Beginner Protocol):

    • Repeat labs: testosterone, LH, FSH, estradiol, SHBG, hematocrit, PSA
    • Semen analysis if fertility goal
    • Testicular volume reassessment
    • Assess: are testicular size and subjective function maintained?

    Decision Tree at Month 3:

    • If testicular size/function well-maintained → continue beginner protocol or progress to intermediate
    • If modest testicular shrinkage or suboptimal response → consider switching to hCG 500 IU 2x weekly (stronger evidence)
    • If significant testicular atrophy or adverse effects → stop, reassess with physician
    • If fertility-specific goal and semen parameters declining → urology consultation for more aggressive intervention

    Red Flags Requiring Stopping:

    • Severe injection site reactions beyond mild erythema
    • New headaches that persist or worsen
    • Rash or any sign of hypersensitivity
    • Unexplained anxiety, mood disturbances (rare but reported)
    • Any signs suggesting increased inflammation or autoimmune activation

    What Beginner Protocol Does NOT Cover:

    • Post-cycle therapy restart protocols (requires different approach)
    • Fertility-specific protocols (refer to urology/reproductive endocrinology)
    • Pump-based pulsatile delivery (requires specialized device and supervision)
    • Women's fertility or hormonal use (requires reproductive endocrinology)
    • Primary hypogonadism (gonadorelin ineffective; refer to endocrinology)
    Standard

    For men who have completed beginner protocols without adverse effects and want to optimize TRT-axis support.

    Intermediate Protocol (Weeks 13-24):

    Option A: Increased Frequency

    • Gonadorelin 100 mcg SC, 3x weekly (Mon/Wed/Fri)
    • Rationale: closer approximation of physiologic pulse frequency
    • More frequent LH pulses may better maintain Leydig cell function

    Option B: Increased Dose

    • Gonadorelin 200 mcg SC, 2x weekly
    • Rationale: larger single pulse may produce more robust LH response
    • Balance: larger dose but less frequent delivery

    Option C: Gonadorelin + hCG Hybrid

    • Gonadorelin 100 mcg SC, Monday/Thursday
    • hCG 250 IU SC, Tuesday/Friday
    • Rationale: direct testicular stimulation (hCG) + pituitary maintenance (gonadorelin)
    • Cost: higher than either alone
    • Evidence: theoretical; no trials

    Option D: Pulse-Mimicking Protocol

    • Gonadorelin 100 mcg SC, every other day
    • Most physiologic frequency pattern achievable without pump
    • Requires commitment to consistent dosing

    Monitoring Schedule (Intermediate):

    • Monthly: subjective symptom review, injection site check, self-monitored testicular size
    • Week 16: labs (testosterone, LH, FSH, estradiol, SHBG, hematocrit, PSA)
    • Week 20: interim symptom check
    • Week 24: comprehensive labs + semen analysis (if fertility goal)

    Advanced Considerations:

    Timing Optimization:

    • Some evidence suggests endogenous GnRH pulses concentrate during sleep onset
    • Evening dosing (8-10 PM) may better mimic physiologic patterns
    • Morning dosing may disrupt natural diurnal rhythm less
    • Patient-specific: consistent timing matters more than specific time

    Cycling vs Continuous:

    • Some protocols use 5 weeks on / 1 week off to prevent potential desensitization
    • Others maintain continuous dosing throughout TRT
    • Evidence is limited; both approaches have theoretical merit
    • Monthly lab monitoring informs the decision

    Dose Adjustments:

    • If testicular size trending down: increase to 150-200 mcg or add hCG
    • If testicular size maintained and function good: reduce to maintenance 100 mcg 2x weekly
    • If LH remains detectable in labs (indicating some pituitary function): protocol is working

    Adverse Event Management:

    • Injection site reactions: rotate sites more aggressively, change to smaller gauge needle
    • Headaches: typically transient; hydration, timing adjustments
    • No response after 12 weeks: switch to hCG rather than increasing gonadorelin dose

    Fertility-Specific Intermediate Protocols: For men specifically targeting fertility during TRT (this often requires specialist involvement):

    • Gonadorelin alone: inadequate evidence; consider hCG
    • Gonadorelin + FSH add-on (Menopur or follitropin): for azoospermia
    • Gonadorelin + hCG + testosterone: may preserve both testicular size and spermatogenesis
    • Semen analysis every 3 months to track response

    When to Progress to Advanced:

    • 6 months of intermediate protocol completed
    • Stable testicular size and function
    • Specific complex scenario (fertility, post-cycle, combination with other peptides)
    • Willingness to invest in more sophisticated monitoring

    When NOT to Progress:

    • Suboptimal response to intermediate protocol (consider HCG substitution instead)
    • Adverse effects or tolerability issues
    • Unclear specific clinical goal
    • Lack of access to appropriate lab monitoring
    Advanced

    For experienced users with complex HPG-axis scenarios, ideally with endocrinology or urology oversight.

    Advanced Use Case 1: Post-Cycle Therapy (PCT) After AAS or Heavy Suppression

    Goal: Restart endogenous HPG axis after prolonged suppression.

    Protocol:

    • Weeks 1-2: Gonadorelin 200 mcg SC, 3x weekly + Enclomiphene 25 mg daily
    • Weeks 3-6: Gonadorelin 200 mcg SC, 3x weekly + Enclomiphene 12.5 mg daily + hCG 500 IU 2x weekly
    • Weeks 7-12: Gonadorelin 100 mcg SC, 2x weekly + Enclomiphene 12.5 mg daily (taper)
    • Month 3-4: Enclomiphene alone 12.5 mg daily, maintenance

    Monitoring:

    • Pre-protocol: comprehensive panel
    • Week 4, 8, 12: LH, FSH, testosterone, estradiol
    • Semen analysis at 12 weeks and 6 months (for fertility assessment)
    • Testicular volume at each milestone

    Expected Timeline:

    • LH/FSH detection: typically within 2-4 weeks
    • Testosterone recovery: 6-12 weeks
    • Semen parameter recovery: 3-6 months
    • Full restoration: 6-18 months in most men

    Advanced Use Case 2: Long-Term TRT Maintenance with Fertility Preservation

    Scenario: Man on long-term TRT who may want future children.

    Protocol:

    • TRT: testosterone cypionate 100-200 mg weekly
    • Gonadorelin 100 mcg SC, 2-3x weekly
    • hCG 500 IU SC, 2x weekly (stronger evidence for fertility preservation)
    • Semen cryopreservation at TRT start (critical insurance policy)
    • Monitor semen parameters every 6 months

    Advanced Use Case 3: Combined Axis Optimization

    Scenario: Comprehensive men's health protocol.

    Protocol:

    Advanced Use Case 4: Pump-Based Pulsatile Delivery (Specialist Only)

    Scenario: Hypogonadotropic hypogonadism requiring physiologic replacement.

    Protocol (Requires Specialist Supervision):

    • Programmable mini-pump (Lutrepulse device or equivalent)
    • 5-25 mcg gonadorelin per pulse every 60-120 minutes
    • Titrated based on LH response and clinical effect
    • Typically managed by reproductive endocrinology

    Complex Monitoring for Advanced Protocols:

    • Quarterly comprehensive hormone panel
    • Semen analysis every 3-6 months for fertility cases
    • Thyroid panel annually (axis interactions)
    • DEXA scan for bone density (baseline and q2y for long-term users)
    • Lipid panel, HbA1c, cardiovascular risk factors annually
    • PSA every 6 months for men 40+
    • Testicular ultrasound baseline and at concerning findings

    Integration with Medical Care: Complex protocols benefit significantly from specialist supervision:

    • Urology or endocrinology for TRT oversight
    • Reproductive endocrinology for fertility-specific protocols
    • Men's health clinics with TRT expertise

    Red Flags for Any Advanced Protocol:

    • Inability to achieve sustained testosterone response
    • Progressive testicular atrophy despite treatment
    • Declining semen parameters
    • New symptoms: severe mood changes, extreme fatigue, unusual fluid retention
    • Abnormal PSA trajectory
    • Development of gynecomastia (estradiol excess)

    Transition Strategies: When gonadorelin is stopped:

    • If on TRT: continue TRT; expect testicular atrophy progression unless hCG added
    • If coming off TRT entirely: taper gonadorelin over 4-6 weeks
    • Post-fertility: gradually transition to simpler regimen

    Combination with Lifestyle Optimization: All advanced protocols should include:

    • Body composition optimization (leptin affects GnRH)
    • Sleep quality optimization (GnRH pulses during sleep)
    • Stress management (cortisol-testosterone interaction)
    • Zinc, vitamin D, magnesium adequacy
    • Moderate exercise, avoiding overtraining (which can suppress HPG axis)

    Commonly Stacked With

    Gonadorelin shares the GnRH decapeptide scaffold with several synthetic analogs but is rarely stacked with them clinically — those analogs (leuprolide, goserelin) produce opposite effects through desensitization. Gonadorelin stacking is typically within the HPG-axis optimization context.

    TRT + Gonadorelin (Most Common Stack): The dominant use case. Testosterone (enanthate, cypionate, or newer formulations) provides physiologic androgen replacement; gonadorelin aims to preserve pituitary-testicular function during androgen-induced HPG suppression.

    • Rationale: maintain LH signaling, preserve intratesticular testosterone, reduce testicular atrophy
    • Limitation: weaker evidence than TRT + HCG, which has decades of documented effectiveness
    • Common combination: TRT + gonadorelin 100 mcg 2-3x weekly

    Gonadorelin + hCG (Dual Axis Support): Some protocols layer both, alternating doses:

    • hCG 250-500 IU 2x weekly (direct Leydig cell stimulation)
    • Gonadorelin 100 mcg 2x weekly on alternate days (pituitary gonadotroph maintenance)
    • Rationale: belt-and-suspenders approach ensuring both pituitary and gonadal tissue remain responsive
    • Concern: may be over-treatment without added benefit

    Gonadorelin + Enclomiphene (Post-Cycle/Recovery): For men restarting HPG axis after androgen suppression:

    • Enclomiphene 12.5-25 mg daily (blocks hypothalamic estrogen receptor negative feedback)
    • Gonadorelin 100-200 mcg 2-3x weekly (direct pituitary stimulation)
    • Rationale: enclomiphene drives endogenous GnRH; gonadorelin provides direct pituitary backup
    • Duration: typically 4-12 weeks post-cycle

    Growth Hormone Axis Combinations: Gonadorelin is sometimes combined with GH-axis peptides in comprehensive "optimization" protocols, though the mechanisms don't overlap:

    • Sermorelin or CJC-1295 + Ipamorelin for GH axis
    • Tesamorelin for GHRH-specific visceral fat reduction
    • Rationale: parallel axis optimization (reproductive + somatotropic)
    • Reality: stacks driven more by clinic business models than biological necessity

    Metabolic/Weight Loss Combinations: Gonadorelin may be included alongside GLP-1 agonists or amylin analogs in men's health clinic protocols:

    • Tirzepatide, Retatrutide, or Semaglutide for weight loss
    • Cagrilintide for amylin-mediated appetite control
    • Rationale: preserve reproductive function during rapid weight loss, which can suppress HPG axis via leptin changes
    • Evidence: limited but mechanistically plausible

    Repair/Recovery Context: Gonadorelin rarely stacks with repair peptides (BPC-157, TB-500) for mechanistic reasons, but these often appear together in comprehensive "longevity" protocols. Combination with Thymosin-Alpha-1 for immune support has no known mechanistic interaction.

    Avoid These Combinations:

    • Gonadorelin + GnRH agonists (leuprolide, goserelin): opposing effects
    • Gonadorelin + GnRH antagonists (cetrorelix, ganirelix): antagonism
    • High-dose daily gonadorelin: risks desensitization
    • Gonadorelin + aromatase inhibitors in men without estradiol monitoring: can crash estrogen

    Nutritional/Lifestyle Stack:

    • Adequate zinc intake (required for LH/FSH production)
    • Vitamin D optimization (supports HPG axis)
    • Stress management (cortisol competes with testosterone production)
    • Sleep quality (GnRH pulses concentrate during sleep in men)
    • Body composition optimization (leptin signaling affects GnRH)

    Side Effects & Safety

    Gonadorelin's side effect profile in pulsatile physiologic dosing is remarkably benign — this is essentially the body's own master reproductive hormone, and when delivered in patterns that mimic endogenous pulsatility, adverse events are minimal. The FDA-approved diagnostic formulation (Factrel, no longer commercially available in the US) and therapeutic pump formulations (Lutrepulse) have been used in thousands of patients with excellent tolerability over decades ([Hoffman and Crowley, 1982](https://pubmed.ncbi.nlm.nih.gov/6749227/)). **Common Mild Side Effects:** - Injection site reactions: redness, pruritus, transient nodule formation (more common with mini-pump catheter sites than intermittent SC bolus) - Headache: mild-to-moderate, usually transient - Nausea: uncommon with SC dosing, more common with IV administration - Flushing: brief facial flushing with IV bolus - Lightheadedness: rare, typically with IV administration **Rare Serious Adverse Events:** - Anaphylactoid/hypersensitivity reactions: <1 per 10,000 doses, but documented with both synthetic gonadorelin and natural GnRH preparations - Phlebitis: with IV administration, particularly at injection site - Paradoxical gonadotropin suppression: with high-frequency or high-dose regimens (see below) **Contrast with GnRH Agonists (Leuprolide, Goserelin):** Unlike leuprolide and goserelin — which cause profound and often prolonged sex hormone suppression with all its consequences (hot flashes, bone loss, mood changes, sexual dysfunction, erectile dysfunction, loss of libido) — pulsatile gonadorelin produces the opposite effect: it supports rather than suppresses the reproductive axis. Confusion between these pharmacologic classes is common and clinically important. **Critical Community Protocol Concerns:** 1. **Continuous vs Pulsatile Risk**: Continuous rather than pulsatile exposure — which can occur with high-frequency or high-dose bolus regimens — risks GnRH receptor desensitization and paradoxical suppression, effectively converting gonadorelin from a gonadotropin-supporting agent into a gonadotropin-suppressing one. The Belchetz monkey experiment demonstrates this principle clearly. 2. **Gender-Specific Considerations**: Women of reproductive age should not use gonadorelin casually for "hormone optimization" protocols because altered GnRH pulsatility can disrupt normal menstrual cyclicity and ovulation. Unintended fertility effects or amenorrhea can result. 3. **Pregnancy**: Relative contraindication outside explicit fertility treatment protocols under specialist supervision. 4. **Pituitary Pathology**: Patients with pituitary adenomas (particularly gonadotroph adenomas) or prior pituitary surgery should avoid gonadorelin without endocrinologist evaluation because pituitary pathology can produce unpredictable responses. 5. **Sourcing/Quality**: The sourcing problem is real — gonadorelin sold through compounding pharmacies and research chemical vendors varies enormously in purity, sterility, and actual peptide content. Third-party analysis of vendor samples has occasionally shown degraded peptide, wrong identity, or bacterial contamination. No pharmaceutical-grade gonadorelin products are currently marketed in the United States for therapeutic use (Factrel was discontinued in 2005). 6. **No Rescue for Primary Hypogonadism**: Gonadorelin does nothing for primary hypogonadism caused by testicular failure itself — if the testes cannot respond to LH stimulation (due to prior damage, Klinefelter syndrome, orchitis, or prolonged AAS-induced atrophy with incomplete recovery), neither gonadorelin nor hCG will restore function. **Long-Term Safety:** Decades of clinical experience with pulsatile pump-based gonadorelin show excellent long-term safety with no documented patterns of cancer, cardiovascular disease, or other serious adverse events attributable to the peptide itself. The bolus TRT-adjunct use case lacks long-term safety data because it is a relatively recent off-label application without dedicated longitudinal studies. **Monitoring for Adverse Events:** - Injection site assessment at each use - Symptom review at 1, 3, 6 months - Pituitary hormone panel (LH, FSH, testosterone, estradiol) every 3-6 months - Testicular volume/symptom assessment - CBC and CMP at baseline and annually

    Contraindications

    **Absolute Contraindications:** - **Known hypersensitivity** to gonadorelin or any GnRH analog - **Pregnancy** outside explicit fertility treatment protocols under specialist supervision - **Active gonadotroph adenoma** (functional pituitary tumor) - **Severe primary hypogonadism** where no response is possible (testicular failure, Klinefelter syndrome with complete failure) - **Current hormone-sensitive cancer** without oncology consultation (prostate, breast) **Relative Contraindications (Require Careful Evaluation):** - **History of pituitary surgery or radiation**: unpredictable response - **Active hormone-sensitive malignancy**: consult oncology - **Severe depression or mood disorders**: HPG axis changes can affect mood - **History of bleeding disorders**: injection technique considerations - **Severe renal or hepatic impairment**: altered peptide clearance - **Uncontrolled hypertension**: reproductive hormones affect vascular tone - **Children under 18**: except diagnostic use under endocrinology **Drug Interactions:** **Medications that May Interfere:** - **GnRH agonists** (leuprolide, goserelin): opposing effects; avoid - **GnRH antagonists** (cetrorelix, ganirelix): direct antagonism; avoid - **Strong dopamine agonists**: may alter GnRH response - **Chronic glucocorticoids**: suppress HPG axis; may reduce effect - **Opioids (chronic high-dose)**: suppress GnRH; may reduce effect **Medications Compatible but Monitor:** - Other peptide therapies (BPC-157, TB-500, GH peptides): no interactions - TRT (testosterone cypionate/enanthate): primary use context - hCG: compatible for dual axis support - Thyroid hormones: HPT axis distinct; generally compatible - Aromatase inhibitors: monitor estradiol carefully **Medical Conditions Requiring Caution:** **Cardiovascular Disease:** - Generally safe; no direct cardiovascular effects - TRT context may have cardiovascular considerations **Metabolic Conditions:** - Diabetes: monitor glucose; peptides sometimes affect insulin sensitivity minimally - Obesity: response may be blunted; consider lifestyle optimization first **Endocrine Conditions:** - Pituitary tumors: absolute contraindication for non-gonadotroph; relative for prolactinoma - Thyroid disease: manage separately; generally compatible - Adrenal insufficiency: stabilize before HPG axis manipulation **Mental Health Conditions:** - Active depression: HPG axis shifts can affect mood - Anxiety disorders: generally compatible; monitor - History of mood disorders: document baseline; monitor **When to Stop Immediately:** - Hypersensitivity/anaphylactoid reaction: stop permanently - New onset significant mood changes: evaluate - Severe injection site reaction: switch administration route or discontinue - Unexpected laboratory changes: investigate **When to Consult Physician:** - Any new symptom during protocol - Unexpected lab values - Progressive testicular atrophy despite treatment - Failure to achieve expected response after 3 months - Complex clinical context (cancer history, multiple medical conditions) - Fertility goals (reproductive endocrinology involvement recommended) - Long-term use beyond 1 year (annual complete reevaluation) **Pre-Existing Conditions Assessment:** Before starting gonadorelin: - Review full medical history - Current medications list - Lab panel (LH, FSH, testosterone, estradiol, CBC, CMP, PSA if 40+) - Semen analysis if fertility is a goal - Testicular examination - Mental health baseline **Monitoring Schedule:** - **Baseline**: complete evaluation - **Month 1**: symptom review - **Month 3**: complete labs + reassessment - **Month 6**: complete labs + semen analysis if indicated - **Month 12**: annual complete reevaluation - **Ongoing**: symptom tracking, quality of life assessment **Integration with Medical Care:** Gonadorelin use, particularly long-term, benefits from clinical oversight: - Primary care with TRT expertise, or - Urology (particularly for fertility-focused use), or - Endocrinology (for complex HPG axis scenarios), or - Men's health clinics with peptide experience Solo use is technically possible but accurate dose adjustment and adverse event management benefit substantially from physician involvement.

    Check interactions with the Interaction Checker →

    Additional Notes

    Standard Dose Ranges (Men's Off-Label Use):

    TRT Adjunct:

    • Conservative: 100 mcg SC, 2x weekly
    • Standard: 100-200 mcg SC, 2-3x weekly
    • Aggressive: 200-300 mcg SC, 2-3x weekly or 100 mcg every other day
    • Frequency matters as much as total dose due to pulsatile physiology

    Post-Cycle Therapy:

    • 100-300 mcg SC, 3x weekly for 4-12 weeks
    • Combined with enclomiphene and/or hCG

    Diagnostic GnRH Stimulation Test (Historical):

    • 100 mcg IV bolus, measure LH/FSH at 0, 30, 45, 60 min
    • Largely obsolete; replaced by baseline panels and imaging

    Pulsatile Pump Therapy (Specialist Only):

    • 5-25 mcg per pulse every 60-120 minutes
    • Requires programmable pump device
    • Physiologic mimicry for hypogonadotropic hypogonadism

    Dose Considerations:

    Why 100 mcg? Community consensus around 100 mcg as starting dose reflects:

    • Sufficient to produce LH response in most users
    • Below typical adverse-event threshold
    • Matches available 2 mg vial dilution math (1 mg/mL → 0.1 mL per dose → 20 doses per vial)

    Why 2-3x Weekly?

    • Gonadorelin half-life is 2-10 minutes; single dose effect is brief
    • 2-3x weekly = intermittent pulses approximating physiology
    • Less frequent: may allow HPG axis suppression to progress
    • More frequent (daily): risks receptor desensitization

    Source Quality Hierarchy:

    1. Pharmaceutical-grade compounding pharmacy: highest quality, USP testing, documented identity/purity
    2. Research-grade from verified vendors: variable; require third-party testing
    3. Grey-market sources: avoid — unknown purity, sterility, identity

    Recognizing Quality:

    • USP-grade certification
    • Third-party COA (certificate of analysis) for peptide identity and purity
    • Proper storage temperature during shipping
    • Lyophilized white powder, reconstitutes clearly
    • No visible particulates in reconstituted solution

    Dose Adjustments:

    Increase Dose/Frequency If:

    • Testicular size declining despite protocol
    • LH undetectable at 4-6 weeks
    • Symptoms suggesting HPG underactivity

    Decrease Dose/Frequency If:

    • Adequate testicular size/function maintained
    • Good LH response
    • Cost consideration with lower-maintenance approach

    Switch Strategies:

    To hCG:

    • Gonadorelin not producing adequate response after 3 months
    • Clear fertility goal with stronger evidence base needed
    • Convenience (hCG longer half-life, less frequent dosing)

    To Enclomiphene Alone:

    • Off TRT trajectory
    • Long-term maintenance without peptide injections
    • Cost optimization

    Off-Protocol:

    • Taper over 4-6 weeks rather than abrupt discontinuation
    • Reassess TRT plan
    • Monitor HPG axis response

    Special Populations:

    Age Considerations:

    • Young men (20s-30s): more responsive; lower doses often sufficient
    • Middle-aged (40s-50s): standard dosing
    • Older men (60+): may require higher doses; lower Leydig cell reserve

    Obesity/Metabolic Syndrome:

    • Peptide absorption variable
    • Consider higher doses in very obese users
    • Underlying metabolic optimization may improve response

    Heavy AAS History:

    • May require higher doses for longer duration
    • Expect prolonged recovery timeline
    • Some individuals have permanent axis damage and won't respond

    Frequently Asked Questions

    What is the recommended Gonadorelin dosage?

    Dosage for Gonadorelin varies by protocol. Consult a qualified healthcare provider.

    How often should I take Gonadorelin?

    Administration frequency depends on the specific protocol. Consult current research literature.

    Does Gonadorelin need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are Gonadorelin side effects?

    Gonadorelin's side effect profile in pulsatile physiologic dosing is remarkably benign — this is essentially the body's own master reproductive hormone, and when delivered in patterns that mimic endogenous pulsatility, adverse events are minimal. The FDA-approved diagnostic formulation (Factrel, no longer commercially available in the US) and therapeutic pump formulations (Lutrepulse) have been used in thousands of patients with excellent tolerability over decades ([Hoffman and Crowley, 1982](https://pubmed.ncbi.nlm.nih.gov/6749227/)). **Common Mild Side Effects:** - Injection site reactions: redness, pruritus, transient nodule formation (more common with mini-pump catheter sites than intermittent SC bolus) - Headache: mild-to-moderate, usually transient - Nausea: uncommon with SC dosing, more common with IV administration - Flushing: brief facial flushing with IV bolus - Lightheadedness: rare, typically with IV administration **Rare Serious Adverse Events:** - Anaphylactoid/hypersensitivity reactions: <1 per 10,000 doses, but documented with both synthetic gonadorelin and natural GnRH preparations - Phlebitis: with IV administration, particularly at injection site - Paradoxical gonadotropin suppression: with high-frequency or high-dose regimens (see below) **Contrast with GnRH Agonists (Leuprolide, Goserelin):** Unlike leuprolide and goserelin — which cause profound and often prolonged sex hormone suppression with all its consequences (hot flashes, bone loss, mood changes, sexual dysfunction, erectile dysfunction, loss of libido) — pulsatile gonadorelin produces the opposite effect: it supports rather than suppresses the reproductive axis. Confusion between these pharmacologic classes is common and clinically important. **Critical Community Protocol Concerns:** 1. **Continuous vs Pulsatile Risk**: Continuous rather than pulsatile exposure — which can occur with high-frequency or high-dose bolus regimens — risks GnRH receptor desensitization and paradoxical suppression, effectively converting gonadorelin from a gonadotropin-supporting agent into a gonadotropin-suppressing one. The Belchetz monkey experiment demonstrates this principle clearly. 2. **Gender-Specific Considerations**: Women of reproductive age should not use gonadorelin casually for "hormone optimization" protocols because altered GnRH pulsatility can disrupt normal menstrual cyclicity and ovulation. Unintended fertility effects or amenorrhea can result. 3. **Pregnancy**: Relative contraindication outside explicit fertility treatment protocols under specialist supervision. 4. **Pituitary Pathology**: Patients with pituitary adenomas (particularly gonadotroph adenomas) or prior pituitary surgery should avoid gonadorelin without endocrinologist evaluation because pituitary pathology can produce unpredictable responses. 5. **Sourcing/Quality**: The sourcing problem is real — gonadorelin sold through compounding pharmacies and research chemical vendors varies enormously in purity, sterility, and actual peptide content. Third-party analysis of vendor samples has occasionally shown degraded peptide, wrong identity, or bacterial contamination. No pharmaceutical-grade gonadorelin products are currently marketed in the United States for therapeutic use (Factrel was discontinued in 2005). 6. **No Rescue for Primary Hypogonadism**: Gonadorelin does nothing for primary hypogonadism caused by testicular failure itself — if the testes cannot respond to LH stimulation (due to prior damage, Klinefelter syndrome, orchitis, or prolonged AAS-induced atrophy with incomplete recovery), neither gonadorelin nor hCG will restore function. **Long-Term Safety:** Decades of clinical experience with pulsatile pump-based gonadorelin show excellent long-term safety with no documented patterns of cancer, cardiovascular disease, or other serious adverse events attributable to the peptide itself. The bolus TRT-adjunct use case lacks long-term safety data because it is a relatively recent off-label application without dedicated longitudinal studies. **Monitoring for Adverse Events:** - Injection site assessment at each use - Symptom review at 1, 3, 6 months - Pituitary hormone panel (LH, FSH, testosterone, estradiol) every 3-6 months - Testicular volume/symptom assessment - CBC and CMP at baseline and annually

    Where can I buy Gonadorelin?

    Visit our vendor directory to find trusted sources for Gonadorelin.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free